Drug shows promise in overcoming endocrine therapy resistance in breast cancer

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Breast cancers diagnosed during the first three years after childbirth, particularly within the first year, may be biologically more aggressive than similar cancers in women who have never given birth, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

For people at high risk of developing breast cancer, yearly mammograms may not be enough to detect tumors early. To make earlier diagnosis easier, a Massachusetts Institute of Technology team has developed portable detectors based on ultrasound, which could be used much more frequently. The team reports that they have improved the resolution of the images produced by their system, making it easier to spot potential tumors, as well as cysts and microcalcifications.

July 10, 2026

Vol.52 No.27

Clinical Roundup

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

MammaPrint + BluePrint can help identify a subset of patients with hormone receptor positive, HER2-negative early-stage breast cancer most likely to benefit from anthracycline-based chemotherapy, according to the results of the prospective FLEX Study (NCT03053193).

July 02, 2026

Vol.52 No.26

Drugs & Targets

FDA approves Trodelvy for first-line treatment of mTNBC

FDA approved Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate, for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.

July 02, 2026

Vol.52 No.26

Clinical Roundup

Neutrophils help triple-negative breast cancer cells spread to other organs, BCM study finds

Researchers at Baylor College of Medicine and collaborating institutions have discovered how immune cells called neutrophils can help triple-negative breast cancer cells metastasize to other organs. The study found these interactions both in animal models and human samples of TNBC.

June 26, 2026

Vol.52 No.25

Clinical Roundup

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.

June 05, 2026

Vol.52 No.22

Drug shows promise in overcoming endocrine therapy resistance in breast cancer

YOU MAY BE INTERESTED IN

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

FDA approves Trodelvy for first-line treatment of mTNBC

Neutrophils help triple-negative breast cancer cells spread to other organs, BCM study finds

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

Renew today!

Subscriber content

Never miss an issue!

Login